TrialBritish journal of clinical pharmacology2018

MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study.

Philip D Ambery et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.